Bugs (probiotics) Are Fighting Back In The World Of Oncology
Bugs (probiotics) Are Fighting Back In The World Of Oncology
First, lets establish what a microbiome is since it is a key term used in this article.
The microbiome is a colony of microbes (bugs) which include bacteria, fungi, protozoa and viruses that live inside and on the outside of every human being (not bugs).
The microbiome is essential for human development,
immunity and nutrition. The bacteria (bugs) living in and on us are not invaders but beneficial colonizers.
Externally, our skins microbiome (many bugs) manages skin conditions such as acne, rosacea, eczema, allergic reactions, elasticity, wrinkles and it’s overall ability to age gracefully.
Internally, autoimmune diseases such as diabetes, rheumatoid arthritis, muscular dystrophy, multiple sclerosis, and fibromyalgia are associated with dysfunctions in the microbiome (a bug party).
Disease-causing microbes (bad bugs) accumulate over time, changing gene activity and metabolic processes and resulting in an abnormal immune response against substances and tissues normally present in and on the body.
Additional information is available about the microbiome and it’s function from the University of Washington: https://depts.washington.edu/ceeh/downloads/FF_Microbiome.pdf
News as of February 2020 has unveiled that the pharmaceutical company named MaaT Pharma has secured major investments to continue their exciting developments in oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.
Hervé Affagard, known as the “healthcare sector paradigm breaker” and co-founder & CEO of MaaT Pharma went on to say, “A growing body of evidence suggests that a functional microbiome can improve cancer outcomes, and we look forward to continue building on our initial proof of concept by going beyond hematological malignancies into solid tumors.”
“MaaT Pharma’s product candidates are based on the company’s proprietary MaaT Microbiome Restoration Biotherapeutics (MMRB) platform. MaaT Pharma’s lead product candidate, MaaT013, is a (bug) enema formulation characterized by a high consistent richness of microbial (bug) species, whose specific bacteria (bugs) are protected thanks to a proprietary (bug) formulation, derived from pooling the full intestinal ecosystems of stringently vetted, healthy donors. The product is manufactured at MaaT Pharma’s centralized European cGMP production facility.” – “MaaT Pharma Announces €18 Million Series B Financing Round” microbiometimes.com, 05 Feb 2020. Web.
Sources:
https://pubmed.ncbi.nlm.nih.gov/collections/59233803/
Click to access FF_Microbiome.pdf